BBB from BBB+. Mallinckrodt MNK "> MNK will double its debt leverage to nearly 5 times in order to acquire Cadence Pharmaceuticals . While the deal gives Mallinckrodt a new platform to build out a hospital-focused pharmaceutical business
billion merger with Questcor. The deal comes less than a month after Mallinckrodt closed its acquisition of Cadence Pharmaceuticals . The transaction will be funded approximately 35% with debt financing, and 65% with shares of Mallinckrodt
Mallinckrodt announced today that is acquiring Cadence Pharmaceuticals for $1.3 billion. The deal gives Mallinckrodt a new platform to build out a hospital-focused pharmaceutical business, but
(Reuters) - Cadence Pharmaceuticals Inc's shares fell to their life-low after the biopharmaceutical company reported a larger-than-expected first-quarter loss on costs related to the recall of its...
We are no longer providing equity research on Cadence Pharmaceuticals CADX . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.
Kurtis Hemmerling submits: A high amount of short-selling may take place in a stock for a few reasons. One may be that analysts may have lowered thier rating or earnings forecasts for a stock. Margins may be sliding and the earning potential for the company is in serious doubt. Such fiscal problems
Cadence Pharmaceuticals CADX reported fourth-quarter results with costs coming in below our expectations. However, this did not have a material impact on
provisions can favor executives over common shareholders. Cadence Pharmaceuticals in-licenses, develops, and markets drugs for the ..... regulations on pain medications could also harm sales. Cadence Pharmaceuticals has won Food and Drug Administration approval of its
Cadence Pharmaceuticals CADX received Food and Drug Administration approval for lead drug candidate Ofirmev, an intravenous acetaminophen. At first glance
We're maintaining our fair value on Cadence Pharmaceuticals CADX as we await a Food and Drug Administration decision on its lead drug candidate Ofirmev (formerly known as Acetavance). The agency has set an action date of November 4.